Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyThoracic TumorsDiseaseNeuroendocrine TumorsSubgroupslightly differentiatedICD10E34.0MeSHNeuroendocrine TumorsSequenceCheckMate 627: NIVO240, NET, C1-8 (PID2820) -|- NIVO480, C9+ (PID2821)ChemotherapyChemo-substanceEverolimusFluorouracilLanreotideLenvatinibNivolumabOctreotideStreptozocinSunitinibChemo-substanceEverolimusFluorouracilLanreotideLenvatinibNivolumabOctreotideStreptozocinSunitinibChemo-substanceEverolimusFluorouracilLanreotideLenvatinibNivolumabOctreotideStreptozocinSunitinibChemo-substanceEverolimusFluorouracilLanreotideLenvatinibNivolumabOctreotideStreptozocinSunitinibNo. Substances12 RadiotherapySupportive therapySupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNo. Substances14Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAbdominal PainAdrenal InsufficiencyAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaAstheniaCholelithiasisConstipationDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Exanthema, AcneiformFatigueHand-Foot SyndromeHeadacheHepatotoxicityHyperglycemiaHypertensionHyperthyroidismHypothyroidismInfectionsLeukopeniaLymphopeniaMucositisNauseaNephritisNeutropeniaOral MucositisPainPneumonitisProteinuriaPruritusRashThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorCapdevila JCaplin MEDilz LMMoertel CGRaymond ERinke ASchuler MYao JCDiseasefortgeschrittener, gut-diff., nicht funktionaler neuroendokriner Tumor der Lunge oder gastrointestinaler Herkunft, Grad 1 und 2, WHO Status 0-1fortgeschrittener oder metastasierter pankreatischer neuroendokriner Tumorfortgeschrittener pankreatisch neuroendokriner Tumorfortgeschrittener pNET oder geNET, Zweitlinie nach TA oder SSA, ECOG 0-1NET, inoperabel oder met., Mitteldarm-Tumor oder unbek. PrimariusNET des Pankreas, met. oder nicht resezierbar, low- oder intermediate-grade, Progress innerhalb der letzten 12 MonateNET des Pankreas, met. oder nicht resezierbar, Progress innerhalb der letzten 12 Monate, ECOG 0-1Neuroendokrine Tumore, entdifferenziert, metastasiert oder lokal fortgeschritten, ECOG 0-1neuroendokrine Tumore, gastroenteropankreatisch, unbekannter Primarius, nicht reserzierbar oder met., Ki-67 Index bis 10%, G1 u G2, ECOG 0-2OriginComprehensive Cancer Center, Mayo Clinic, Rochester, MNDept. of Hepatology and Gastroenterology, Campus Virchow Klinikum, Charite, BerlinService Inter-Hospitalier de Cancérologie et de Gastroenteropancréatologie, Hôpital Beaujon, Clichy, FrankreichThe CLARINET Investigators, CLARINET StudieThe Fourth Trial (RADIANT-4) Study GroupThe PROMID Study Group, PROMID StudieThe Third Trial (RADIANT-3) Study GroupVHIO, Barcelona, Spain, TALENT Trial (GETNE1509)West German Cancer Center Essen, University Hospital Essen, Essen, GermanyProtocols in Revision 10 protocols foundProtocols under revision.Everolimus 10, Pancreatic Neuroendocrine Tumor (PID560 V1.0)Everolimus 10, Pulmonary and Gastroenteric Neuroendocrine Tumors (PID650 V1.2)Fluorouracil 400 / Streptozocin 500, Neuroendocrine Tumor (PID1399 V1.0)Fluorouracil 400 / Streptozocin 500, Neuroendocrine Tumor (PID643 V1.0)Lanreotide 120, Neuroendocrine Tumor (PID542 V1.0)Lenvatinib 24, Gastroenteric and Pancreatic Neuroendocrine Tumors (PID2018 V1.0)Nivolumab 240, Neuroendocrine Tumors, Cycle 1-8 (PID2820 V1.0)Nivolumab 480, Neuroendocrine Tumors, Cycle 9+ (PID2821 V1.0)Octreotide LAR 30, gastroenteric and pancreatic Neuroendocrine Tumor (PID543 V1.0)Sunitinib 37.5, pancreatic Neuroendocrine Tumor (PID561 V1.0)
